Added prostate CA criteria may help ID surveillance candidates

January 24, 2014
Added prostate CA criteria may help ID surveillance candidates

(HealthDay)—Additional predictors, such as prostate-specific antigen (PSA) density and extent of cancer on biopsy, help guide selection of prostate cancer patients for active surveillance programs, according to research published in the February issue of The Journal of Urology.

In an effort to identify predictors of adverse pathology, Annelies Vellekoop, M.D., of New York University in New York City, and colleagues analyzed data for 4,500 men who underwent for Gleason 6 . The researchers included a subset with extended biopsy data.

The researchers found that, based on the inclusion criteria of six currently published protocols, 33 to 45 percent of men with clinically localized Gleason 6 prostate cancer had adverse pathology at radical prostatectomy. Predictors of upgrading and up staging among patients with Gleason 6 prostate cancer included older age, higher levels of PSA, PSA density greater than 0.15 ng/ml/cm³, palpable disease, and extent of cancer greater than 4 mm on biopsy. Larger prostate volume was inversely related to adverse pathology.

"More than a third of men meeting the most stringent active surveillance criteria had adverse pathology at radical prostatectomy in this population-based cohort," the authors write. "Active surveillance programs should consider PSA density and extent of cancer on biopsy for patient selection."

One author disclosed financial ties to Sanofi.

Explore further: Implications of very low risk prostate cancer assessed

More information: Abstract
Full Text

Related Stories

Implications of very low risk prostate cancer assessed

September 20, 2013
(HealthDay)—The risk of adverse findings at surgery for men with very low risk (VLR) prostate cancer is significantly lower than for those with low risk (LR), according to research published in the October issue of the ...

Radical prostatectomy doesn't cut mortality versus observation

July 19, 2012
(HealthDay) -- For men with clinically localized prostate cancer, radical prostatectomy does not significantly reduce all-cause or prostate-cancer mortality compared with observation through 12 years of follow-up, according ...

New early detection test for prostate cancer: Mi-Prostate Score test improves on PSA for predicting cancer

September 26, 2013
More than 1 million men will undergo a prostate biopsy this year, but only about one-fifth of those biopsies will result in a cancer diagnosis.

Prostate cancer screening: New data support watchful waiting

August 14, 2013
Prostate cancer aggressiveness may be established when the tumor is formed and not alter with time, according to a study published in Cancer Research, a journal of the American Association for Cancer Research.

Physical symptoms from prostate biopsy can cause anxiety

October 23, 2013
(HealthDay)—Problematic symptoms of prostate biopsy can lead to increased anxiety in men, even when the biopsy results are negative for cancer, according to research published online Oct. 21 in the Journal of Clinical Oncology.

Racial discrepancy in oncologic outcomes for low-risk PCa

June 18, 2013
(HealthDay)—Among men with very-low-risk prostate cancer (PCa) who meet criteria for active surveillance but undergo radical prostatectomy, African-American race is associated with poorer outcomes, with higher rates of ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.